iPSC & Pluripotent Stem Cells
Built For This Cell Type.
Homogeneous mixing prevents aggregate merging during expansion and medium exchange, keeping size distributions narrow for reproducible differentiation.
The same low-shear, low-EDR regime from 0.1 L to 80 L, characterized by CFD, so a process tuned small transfers up predictably.
Preserves pluripotency and enables uniform differentiation into islets, organoids and downstream lineages.
Applications
- hiPSC / PSC expansion
- Aggregate culture
- Microcarrier culture
- Directed differentiation
- SC-islets
- Organoids
- High-density cell banking
Systems for This Cell Type
Each system carries the note explaining why it suits this cell type.
- PBS-MiniFeasibility & aggregate optimization
- PBS-MiniPRO24× parallel media / feed DoE
- PBS-3GMP-ready tech transfer
- PBS-15Clinical batches with perfusion MX
- PBS-80Commercial supply, linear to 80 L
hiPSC expansion scaled linearly across the full Vertical-Wheel® range while maintaining aggregate quality.
The Data Behind It.
This protocol provides step-by-step guidance for transitioning pluripotent stem cells (PSCs) from 2D adherent culture to scalable 3D aggregate culture using the PBS-Mini Vertical-Wheel® bioreactor. It covers seed train preparation, inoculation, aggregate formation, expansion, media exchange, sampling, morphology assessment, cell counting, viability analysis, and harvest. Workflows are provided for both PBS-Mini 0.1 and 0.5 vessels, including aggregate dissociation in conical tubes or directly within the bioreactor. The protocol offers a practical starting point for developing, optimizing, and scaling robust PSC aggregate processes on the PBS Vertical-Wheel platform.
This study combines CFD simulations with hPSC suspension culture experiments to investigate scale-up in Vertical-Wheel® bioreactors. The authors compare conventional Eulerian metrics, including volume-averaged shear stress and energy dissipation rate (EDR), with Lagrangian analysis of aggregate trajectories. Aggregate size, agitation rate, and bioreactor scale were shown to influence hydrodynamic exposure, while EDR correlated more strongly with aggregation efficiency, aggregate size, and cell expansion than shear stress. The findings highlight the value of tracking aggregate exposure histories to guide more representative scale-up and agitation strategies for hPSC manufacturing in Vertical-Wheel bioreactors.
This white paper examines the cost and operational advantages of scaling cell therapy manufacturing with Vertical-Wheel® bioreactors compared with planar culture and stirred-tank systems. It evaluates expansion efficiency, labor, facility footprint, process consistency, contamination risk, and cell quality. Published studies in hiPSCs and MSCs are used to assess yield, handling requirements, reproducibility, viability, phenotype, potency, and scale-up performance. A side-by-side cost comparison, including a 3 L PBS Biotech system, illustrates how Vertical-Wheel bioreactors can support a more streamlined and scalable manufacturing approach while recognizing that actual costs depend on the specific process.
This poster evaluates the MiniPRO, a scaled-down, computer-controlled Vertical-Wheel® bioreactor platform, for expansion of human induced pluripotent stem cells (iPSCs). Oxygen-controlled MiniPRO cultures were compared with non-controlled systems across conventional inoculation and direct-thaw workflows. Results showed consistent aggregate size distributions, preservation of pluripotency markers SOX2 and OCT4, and enhanced process control through dissolved oxygen regulation. Scale-up studies demonstrated comparable growth kinetics, metabolite profiles, and aggregate characteristics between MiniPRO and PBS-3L systems, supporting MiniPRO as a representative scale-down model for efficient process development and reduced scale-up risk in PSC manufacturing.
Talk Through Your Process.
Our scientists work on these processes daily. Bring us your cell type, your scale and your constraints.